<DOC>
	<DOCNO>NCT00003241</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness phenylacetate treat child recurrent progressive brain tumor .</brief_summary>
	<brief_title>Phenylacetate Treating Children With Recurrent Progressive Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy phenylacetate term response rate time progression child recurrent progressive brain tumor , previously untreated poor prognosis brain tumor . II . Assess toxicity phenylacetate patient treat maximum tolerated dose . III . Determine correlation serum steady state phenylacetate level toxicity response patient . OUTLINE : Patients stratify histologic type ( anaplastic astrocytoma glioblastoma multiforme v brain stem glioma v medulloblastoma primitive neuroectodermal tumor vs ependymoma vs low grade glioma v others ) . Patients receive phenylacetate continuous intravenous infusion day 1-28 . Courses treatment give continuously without rest . Treatment continue absence disease progression unacceptable toxicity . Patients follow weekly . PROJECTED ACCRUAL : A total 9-30 patient per stratum accrue study 2 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Phenylacetic acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent progressive brain tumor include follow : Anaplastic astrocytoma glioblastoma multiforme Brain stem glioma Medulloblastoma primitive neuroectodermal tumor present supratentorial posterior fossa location Ependymoma Low grade glioma Other Measurable evaluable disease CT MRI OR Histologically confirm previously untreated glial tumor include : Brain stem glioma Glioblastoma multiforme Measurable disease surgery PATIENT CHARACTERISTICS : Age : 2 21 Performance status : Karnofsky 50100 % ( 10 year age ) Lansky 50100 % ( 10 year age ) Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 50,000/mm3 Hemoglobin great 7.0 g/dL Transfusion support allow bone marrow transplantation extensive radiation Hepatic : Bilirubin le 1.5 mg/dL SGPT le 2 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception 6 month study No significant systemic illness include infection No amino acidurias organic acidemia PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior immunotherapy No concurrent prophylactic hematopoietic growth factor Chemotherapy : At least 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosourea ) recover No concurrent cancer chemotherapy Endocrine therapy : Stable decrease dosage dexamethasone intracranial pressure within 2 week study entry No concurrent dexamethasone use antiemetic Radiotherapy : At least 8 week since prior radiotherapy evaluable lesion recover Surgery : At least 4 month since prior radiosurgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
</DOC>